RFG Advisory’s Corbus Pharmaceuticals CRBP Stock Holding History

RFG Advisory’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-394	Closed	-$65K	–	359
2019 Q4	$65K	Sell	394 -67	-15%	-$9.9K	0.01%	363
2019 Q3	$67K	Buy	+461	New	+$80.3K	0.01%	331

Other funds holding CRBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RFG Advisory's CRBP Position: Q1 2020 in Review

RFG Advisory sold out of Corbus Pharmaceuticals (CRBP) in Q1 2020, closing a stake of 394 shares — an estimated $65K sold.

RFG Advisory first reported a position in CRBP in Q3 2019 and held it in 2 quarters. The position peaked at $67K in Q3 2019. 111 funds tracked by Wall St. Rank hold CRBP as of Q1 2020.

RFG Advisory reported no remaining Corbus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
RFG Advisory sold 394 Corbus Pharmaceuticals shares in Q1 2020, an estimated $65K.
RFG Advisory first reported a position in Corbus Pharmaceuticals in Q3 2019 and held it in 2 quarters.
RFG Advisory's Corbus Pharmaceuticals position peaked at $67K in Q3 2019.
111 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2020.

Based on RFG Advisory's 13F filing for Q1 2020, filed 17 Apr 2020.